Lexaria Bioscience Beheer

Beheer criteriumcontroles 1/4

De CEO Lexaria Bioscience is Rich Christopher, benoemd in Aug2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde $ 89.00K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.4 jaar en 2.1 jaar.

Belangrijke informatie

Rich Christopher

Algemeen directeur

US$519.3k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

CEO

Rich Christopher (54 yo)

less than a year

Tenure

US$519,317

Compensatie

Mr. Richard C. Christopher, also known as Rich, is Chief Executive Officer of Lexaria Bioscience Corp. from August 31, 2024 and served as its Director since 2025. He served as Chief Financial Officer and T...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Christopher	CEO & Director	less than a year	US$519.32k	0.28% $ 89.0k
John Docherty	Chairman of the Scientific Advisory Board	9.8yrs	US$414.42k	0% $ 0
Michael Shankman	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Kristin Hamilton	Director of Operations	no data	geen gegevens	geen gegevens
Vanessa Carle	Head of Legal	no data	geen gegevens	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

0.4yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LEXX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Christopher	CEO & Director	less than a year	US$519.32k	0.28% $ 89.0k
John Docherty	Chairman of the Scientific Advisory Board	8.8yrs	US$414.42k	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Albert Reese	Independent Director	4.1yrs	US$74.83k	0.062% $ 19.4k
Christopher Bunka	Chairman of the Board	18.3yrs	US$884.84k	2.13% $ 664.9k
Nicholas Baxter	Independent Director	13.6yrs	US$74.83k	0.063% $ 19.6k
William McKechnie	Independent Director	9.4yrs	US$69.83k	0.075% $ 23.5k
Baljinder Bhullar	Director	less than a year	geen gegevens	0.074% $ 23.1k
Philip Ainslie	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Karen Aust	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LEXX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/02/09 02:50
Aandelenkoers aan het einde van de dag	2025/02/07 00:00
Inkomsten	2024/11/30
Jaarlijkse inkomsten	2024/08/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Lexaria Bioscience Corp. wordt gevolgd door 4 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Ammar Shah	Eight Capital
Yi Chen	H.C. Wainwright & Co.
Michael Okunewitch	Maxim Group

Lexaria Bioscience Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Chief Executive Officer recently bought US$51k worth of stock

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Recent updates

Lexaria Bioscience Corp. Announces Dosing Has Begun in Its Fluorescently Tagged Dehydratech-Semaglutide Rodent Biodistribution Study

New major risk - Revenue and earnings growth

Less than half of directors are independent

Consensus revenue estimates fall by 12%

Lexaria Bioscience Corp. Announces Partial Final Results Showcasing the Tolerability and Glycemic Control Efficacy Findings from Human Study GLP-1- H2 4-3

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Begins Dosing in its Phase 1B, 12-Week Chronic Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide

Chief Executive Officer recently bought US$51k worth of stock

Consensus revenue estimates fall by 13%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria Bioscience Corp.'s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study

Consensus revenue estimates fall by 24%

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products